-

Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products

ATLANTA--(BUSINESS WIRE)--Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing rare disease therapies with an integrated solution to support the commercialization of their products.

“The goal of this collaboration is to transform the way Rare and Orphan therapies are introduced to market, ensuring they reach the patients who need them most.” -Patrick Dunham, CEO and Co-Founder of Curant Health

Share

Rare disease therapies face unique challenges, including complex regulatory pathways and access barriers. This collaboration will leverage Cencora’s pharmaceutical logistics services and commercialization solutions, such as pharmacovigilance and market access support, and Curant Rare’s specialty pharmacy services and omnichannel patient engagement solutions.

The integrated solution aims to streamline the path to commercialization, helping pharmaceutical companies bring therapies to market more efficiently, optimize the patient journey and help expedite speed-to-therapy.

“Our combined efforts focus on overcoming challenges in access and implementation,” said Patrick Dunham, CEO and Co-Founder of Curant Health. “The goal of this collaboration is to transform the way Rare and Orphan therapies are introduced to market, ensuring they reach the patients who need them most.”

Through the collaboration, pharmaceutical companies will have access to advanced tools designed to improve the patient experience, such as actionable insights into real-world evidence and patient-reported outcomes. To learn more about the initiative, visit: https://www.cencora.com/initiatives/pharma/a-unified-mission-transform-rare-disease-care

About Curant Rare

Curant Rare, a specialized Curant Health Business Unit, provides bespoke specialty pharmacy and Real-World Evidence solutions to provide best-in-class rare disease patient and provider journeys. Curant Rare’s personalized approach to patient care focuses on rare and ultra-rare patient populations to improve outcomes in measurable and meaningful ways. Curant Rare provides comprehensive high-quality care while placing the patient's physical and psychosocial well-being as a priority through their validated Medication Care Management® services. With over 25 years of experience, Curant Rare brings a proven track record in best-in-class patient adherence and Quality of Life.

For more information, please visit curantrare.com.

Contacts

Media Contact
Culver Lyons
Associate Director of Marketing
clyons@curanthealth.com

Curant Rare LogoCurant Rare Logo

Curant Rare


Release Versions

Contacts

Media Contact
Culver Lyons
Associate Director of Marketing
clyons@curanthealth.com

Social Media Profiles
More News From Curant Rare

Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics

ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated access to therapy, and comprehensive support to help patients and caregivers navigate the complexities of treatment. Patients will now benefit from Curant Rare’s proven high-touch care model, designed to ensure timely access to medication, address treatment barriers such as insurance and financial concerns, and...

Curant Rare Announces Exclusive Pharmacy Partnership for IWILFIN™, the First and Only FDA-Approved Oral Maintenance Therapy Shown to Cut the Risk of High-Risk Neuroblastoma Relapse in Half

ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare is now the exclusive pharmacy partner for IWILFIN™, a groundbreaking therapy used to reduce the risk of relapse in adults and children with high-risk neuroblastoma (HRNB). Beginning in August 2025, patients will transition to Curant Rare with one clear goal in mind: to ensure uninterrupted access to care while enhancing the patient and caregiver experience through the IWILFIN Cares® program. All patients will continue...

Curant Health and The University of Kansas School of Medicine-Wichita Medical Practice Association Unveil New On-Site Pharmacy

WICHITA, Kan.--(BUSINESS WIRE)--Curant Health, a leading national specialty pharmacy serving communities for over 25 years, officially announces the opening of its new on-site pharmacy at The University of Kansas School of Medicine-Wichita Medical Practice Association. This new location seeks to enhance patient convenience and deliver comprehensive care by seamlessly combining doctor visits with pharmacy services. The partnership between Curant Health and KU Wichita Medical Practice Association...
Back to Newsroom